Cresco Labs Inc. (OTCMKTS:CRLBF – Get Rating) – Research analysts at Echelon Wealth Partners issued their Q2 2022 earnings estimates for Cresco Labs in a research note issued on Wednesday, May 18th. Echelon Wealth Partners analyst A. Semple forecasts that the company will earn $0.01 per share for the quarter. Echelon Wealth Partners currently has a “Buy” rating on the stock. Echelon Wealth Partners also issued estimates for Cresco Labs’ Q3 2022 earnings at $0.03 EPS, Q4 2022 earnings at $0.03 EPS, FY2022 earnings at $0.00 EPS and FY2023 earnings at $0.28 EPS.
CRLBF has been the topic of several other reports. Alliance Global Partners dropped their target price on shares of Cresco Labs from C$19.00 to C$15.00 in a report on Thursday. Zacks Investment Research downgraded shares of Cresco Labs from a “hold” rating to a “sell” rating in a report on Monday, May 9th. Canaccord Genuity Group dropped their target price on shares of Cresco Labs from C$12.00 to C$9.50 in a report on Thursday. Piper Sandler lowered their price objective on shares of Cresco Labs from $14.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, March 24th. Finally, Atb Cap Markets reiterated an “outperform” rating on shares of Cresco Labs in a report on Wednesday, March 23rd. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $16.79.
Cresco Labs Company Profile (Get Rating)
Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand.
- Get a free copy of the StockNews.com research report on Cresco Labs (CRLBF)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Cresco Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cresco Labs and related companies with MarketBeat.com's FREE daily email newsletter.